title: Overexpression of CD99 Increases the Migration and Invasiveness of Human Malignant Glioma Cells.
abstract: The malignant glioma is the most common primary human brain tumor, and its migration and invasiveness away from the primary tumor mass are considered a leading cause of tumor recurrence and treatment failure. Recently, gene expression profiling revealed that the transmembrane glycoprotein CD99 is more highly expressed in malignant glioma than in normal brain. Although its function is not completely understood, CD99 is implicated in cell adhesion and migration in a variety of different cell types. CD99 has wild-type and splice variant isoforms. Previous studies have shown that wild-type CD99 may be an oncosuppressor in some tumors, distinct from the role of the splice variant isoform. In this study, our data reveal that only wild-type CD99 is expressed in human glioma cells and tissues. Using a tissue microarray, we validated that gliomas demonstrate higher expression of CD99 compared with nonneoplastic brain. To assess the role of CD99 in glioma migration and invasion, we inhibited CD99 expression by siRNA and demonstrated decreased glioma migration and invasion. In contrast, when CD99 was overexpressed in glioma cells, we observed enhancement of cell migration and invasiveness. An orthotopic brain tumor model demonstrates that CD99 overexpression significantly increases invasiveness and decreases survival rate. Interestingly, Rac activity was decreased and Rho activity was increased in CD99 overexpressing glioma cells, and the proportion of amoeboid cells to mesenchymal cells was significantly increased. Taken together, our findings suggest that CD99 may play an important role in the migration and invasion of human gliomas independent of Akt, ERK, or JNK signaling pathways. Moreover, CD99 might be involved in amoeboid-mesenchymal transition in glioma migration. CD99 may be an important future target to inhibit migration and invasion, especially in CD99-expressing gliomas.
authors.affiliation: Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada ; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (R.O.K.).
authors.forename: Ho Jun
authors.initials: HJ
authors.lastname: Seol
authors.forename: Jong Hee
authors.initials: JH
authors.lastname: Chang
authors.forename: Junkoh
authors.initials: J
authors.lastname: Yamamoto
authors.forename: Rocco
authors.initials: R
authors.lastname: Romagnuolo
authors.forename: Youngchul
authors.initials: Y
authors.lastname: Suh
authors.forename: Adrienne
authors.initials: A
authors.lastname: Weeks
authors.forename: Sameer
authors.initials: S
authors.lastname: Agnihotri
authors.forename: Christian A
authors.initials: CA
authors.lastname: Smith
authors.forename: James T
authors.initials: JT
authors.lastname: Rutka
keywords: CD99; amoeboid; glioma; invasion; mesenchymal; migration